Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 78

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 78
---
 of revocation, which is dated later than the date of the proxy and states that                
 the proxy is revoked, to Enfusion, Inc., Attention: Legal Department, 125 South Clark Street, Suite 750, Chicago, IL 60603; or |

| • |     | participating in and voting during the virtual Special Meeting. Participation in the virtual Special Meeting will 
 not, however, in and of itself, constitute a vote or revocation of a prior proxy.                                 |

Enfusion beneficial owners may change their voting instruction only by following the directions received from their bank, brokerage firm or other nominee for changing their voting instructions. 48

Solicitation of Proxies

Enfusion will pay for the proxy solicitation costs related to the Special Meeting. In addition to sending and making available these materials,
some of Enfusion’s directors, officers and employees may solicit proxies in person by contacting Enfusion Stockholders by telephone or over the Internet. Enfusion Stockholders may also be solicited by press releases issued by Enfusion, postings
on Enfusion’s websites and advertisements in periodicals. None of Enfusion’s directors, officers or employees will receive additional compensation for their solicitation services. Enfusion has engaged Innisfree to assist in the
solicitation of proxies for the Special Meeting. Enfusion estimates that it will pay Innisfree a fee of approximately $20,000, plus reasonable out-of-pocket expenses.
Certain banking institutions, brokerage firms, custodians, trustees, nominees and fiduciaries who hold shares for the benefit of another party may solicit proxies for Enfusion. If so, they will mail proxy information to, or otherwise communicate
with, the beneficial owners of shares of Enfusion Common Stock held by them. Enfusion will also reimburse banks, brokerage firms, custodians, trustees, nominees and fiduciaries for their expenses incurred in sending proxies and proxy materials to
beneficial owners of Enfusion Common Stock.

Adjournments

The Special Meeting may be adjourned by the presiding officer or Enfusion Stockholders representing a majority of the voting power present at
the Special Meeting if no quorum is present, or by the presiding officer if (i) the Enfusion Board determines that adjournment is necessary or appropriate to enable Enfusion Stockholders to consider fully information which the Enfusion Board
determines has not been made sufficiently or timely available to stockholders, or (ii) if the Enfusion Board determines that adjournment is otherwise in the best interests